GENEURO
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody for the treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland.
GENEURO
Industry:
Biotechnology Health Care Therapeutics
Founded:
2006-01-01
Address:
Geneva, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.geneuro.com
Total Employee:
11+
Status:
Active
Contact:
+41227945085
Total Funding:
41.77 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics Content Delivery Network Google Universal Analytics Apache Euro PHP
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Institut Merieux
Institut Merieux investment in Post-IPO Equity - GeNeuro
Invesco
Invesco investment in Post-IPO Equity - GeNeuro
Federal Office of Public Health (FOPH) Switzerland
Federal Office of Public Health (FOPH) Switzerland investment in Grant - GeNeuro
Eclosion SA
Eclosion SA investment in Venture Round - GeNeuro
Key Employee Changes
| Date | New article |
|---|---|
| 2020-04-21 | GeNeuro Appoints MS Clinical Development Expert Dr. David Leppert as Chief Medical Officer |
Official Site Inspections
http://www.geneuro.com Semrush global rank: 7.53 M Semrush visits lastest month: 462
- Host name: h2web367.infomaniak.ch
- IP address: 83.166.133.74
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "GeNeuro"
Geneuro
[email protected]; X-twitter Linkedin Youtube. Results of the GNC-501 study. June 2024 ...See details»
Company Overview - Geneuro
GeNeuro has also entered into a partnership with the National Institute of Neurological Disorders and Stroke (NINDS, part of the NIH), as NINDS evidenced the potential role of another HERV …See details»
GeNeuro - Crunchbase Company Profile & Funding
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The …See details»
The Board of GeNeuro – Geneuro
This unique structure was instrumental in the creation of GeNeuro, which was led by Jesús since its creation in 2006. Jesús holds a bachelor's degree in industrial sciences, a master in law …See details»
Company History – Geneuro
GeNeuro launches a formal preclinical effort aiming to obtain an IND by mid-2020. Signing of a financing agreement with GNEH SAS, a subsidiary of Institut Mérieux, to establish a €7.5 …See details»
GeNeuro SA – Swiss Biotech
GeNeuro is a Phase2 clinical-stage company that develops antibodies to neutralize patient-produced pathogenic proteins that fuel a great number of neurodegenerative and autoimmune …See details»
GeNeuro Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other …See details»
GeNeuro - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised ... Mar 7, 2023: Post-IPO Debt - GeNeuro . 1: …See details»
GeNeuro - Contacts, Employees, Board Members, Advisors & Alumni
Organization. GeNeuro . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of Board …See details»
GeNeuro: Financial Information and Business Update for the …
Jul 23, 2021 GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552 4800 [email protected] NewCap (France) Louis-Victor Delouvrier / Mathilde Bohin (investors) …See details»
Company governance - GeNeuro
Jun 14, 2023 3, Chemin du Pré-Fleuri CH-1228 Plan-les-Ouates. +41 22 552 48 00; [email protected]; X-twitter Linkedin Youtube Linkedin YoutubeSee details»
GeNeuro and Verily Collaborate to Advance Long-COVID Research
Oct 19, 2023 GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552 4800 [email protected] NewCap (France) Louis-Victor Delouvrier +33 1 44 71 98 52 Arthur …See details»
GeNeuro Reports 2020 Full-Year Results and Provides Corporate …
Apr 6, 2021 GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552 4800 [email protected] NewCap (France) Mathilde Bohin / Louis-Victor Delouvrier (investors) …See details»
GeNeuro’s main shareholders – Geneuro
Servier is an independent French pharmaceutical company, which was GeNeuro’s former development partner in multiple sclerosis. Its development is based on the continuous pursuit …See details»
GeNeuro Reports 2021 Full-Year Results and Provides Corporate …
Apr 4, 2022 Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimSee details»
GeNeuro secures EUR 5 million to advance post-COVID and ...
Feb 5, 2024 GeNeuro, a company known for its pioneering work in neurodegenerative and autoimmune diseases, has successfully completed a EUR 5 million capital increase. GeNeuro, …See details»
News & Press - Geneuro
Sep 19, 2024 GeNeuro Announces Approval of all Resolutions Proposed at 2024 Annual General Meeting. Geneva, Switzerland, June 14, 2024 – 6:30pm CEST – GeNeuro (Euronext …See details»
GeNeuro: One of the largest trials against long-COVID
Nov 28, 2023 GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and …See details»
GeNeuro: Financial Information and Business Update for the …
Jul 21, 2022 GeNeuro Jesús Martin-Garcia President and CEO +41 22 552 4800 [email protected] NewCap (France) Mathilde Bohin / Louis-Victor Delouvrier (investors) …See details»
Pipeline Overview - GeNeuro
GeNeuro’s most advanced therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W (W-ENV) family identified as a …See details»